NCT03773965招募中3 期
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 190
- 试验地点
- 93
- 主要终点
- Number of Participants with One or More Serious Adverse Event(s) (SAEs)
研究概览
简要总结
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have completed a previous study of baricitinib for the treatment of JIA.
排除标准
- •Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- •Participants must have not developed an allergy to baricitinib.
研究组 & 干预措施
Baricitinib
Experimental
Baricitinib given orally.
干预措施: Baricitinib (Drug)
结局指标
主要结局
Number of Participants with One or More Serious Adverse Event(s) (SAEs)
时间窗: Baseline through Week 264
Number of participants with one or more SAEs
Number of Participants with Permanent Investigational Product Discontinuations
时间窗: Baseline through Week 264
Number of participants with permanent investigational product discontinuations
次要结局
- Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index(Baseline, Week 264)
- Change from Baseline in Juvenile Spondyloarthritis Disease Activity Index (JSpADA)(Baseline, Week 264)
- Change from Baseline in Immunoglobulin Levels(Baseline, Week 264)
- Change from Baseline in Immunophenotyping (T Cells)(Baseline, Week 264)
- Change of Immunoglobulin G (IgG) Titers(Pre-Vaccination to 12 Weeks Post-Vaccination)
- Proportion of Participants with Inactive Disease(Week 264)
- Proportion of Participants with Minimal Disease Activity(Week 264)
- Proportion of Participants in Remission(Week 264)
- Change from Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS27)(Baseline, Week 264)
- Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item(Baseline, Week 264)
- Change from Baseline in Psoriasis Area and Severity Index (PASI)(Baseline, Week 264)
- Proportion of Participants Achieving Pediatric American College of Rheumatology 30 Responder Index (PedACR30)(Week 264)
- Proportion of Participants who have Disease Flare(Baseline through Week 264)
研究者
研究点 (93)
Loading locations...
相似试验
已完成
3 期
An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01885078Eli Lilly and Company2,877
已完成
3 期
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisAtopic DermatitisNCT03334435Eli Lilly and Company1,645
终止
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT03843125Eli Lilly and Company1,147
招募中
3 期
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataAreata AlopeciaHypotrichosisHair DiseasesSkin DiseasesPathological Conditions, AnatomicalAlopeciaNCT05723198Eli Lilly and Company595
已完成
3 期
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisAtopic DermatitisNCT03952559Eli Lilly and Company516